• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia Receiving Acalabrutinib in the Phase 3B ASSURE Study.

作者信息

Niemann Carsten U, Awan Farrukh T, Fogliatto Laura, Nikitin Eugene, Samoilova Olga, Habib Adel, Foroutanpour Kayhan, Kuptsova-Clarkson Nataliya, Opat Stephen

机构信息

Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

出版信息

Hemasphere. 2022 Sep 22;6(10):e780. doi: 10.1097/HS9.0000000000000780. eCollection 2022 Oct.

DOI:10.1097/HS9.0000000000000780
PMID:36168519
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9509175/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de52/9509175/69900172efcc/hs9-6-e780-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de52/9509175/69900172efcc/hs9-6-e780-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de52/9509175/69900172efcc/hs9-6-e780-g001.jpg

相似文献

1
COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia Receiving Acalabrutinib in the Phase 3B ASSURE Study.在3B期ASSURE研究中接受阿卡替尼治疗的慢性淋巴细胞白血病患者的COVID-19感染情况
Hemasphere. 2022 Sep 22;6(10):e780. doi: 10.1097/HS9.0000000000000780. eCollection 2022 Oct.
2
An update on acalabrutinib to treat chronic lymphocytic leukemia.阿卡替尼治疗慢性淋巴细胞白血病的最新进展。
Drugs Today (Barc). 2021 Jul;57(7):417-431. doi: 10.1358/dot.2021.57.7.3285932.
3
EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.EMA 对阿卡替尼治疗成人慢性淋巴细胞白血病的评估。
Oncologist. 2021 Mar;26(3):242-249. doi: 10.1002/onco.13685. Epub 2021 Feb 10.
4
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.阿卡替尼、维奈托克和奥滨尤妥珠单抗作为慢性淋巴细胞白血病的一线治疗：一项单臂、开放标签、2 期研究。
Lancet Oncol. 2021 Oct;22(10):1391-1402. doi: 10.1016/S1470-2045(21)00455-1. Epub 2021 Sep 14.
5
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.阿卡替尼联合或不联合奥滨尤妥珠单抗对比苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（ELEVATE TN）：一项随机、对照、III 期临床试验。
Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.
6
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.阿卡替尼：一种用于治疗慢性淋巴细胞白血病的布鲁顿酪氨酸激酶抑制剂。
Expert Rev Hematol. 2022 Mar;15(3):183-194. doi: 10.1080/17474086.2022.2054800. Epub 2022 Mar 29.
7
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.ASCEND：阿卡替尼对比伊布替尼联合利妥昔单抗或苯达莫司汀联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病的 III 期随机试验。
J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27.
8
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.阿卡拉布替尼用于对依鲁替尼不耐受的复发/难治性慢性淋巴细胞白血病患者的II期研究。
Haematologica. 2021 Sep 1;106(9):2364-2373. doi: 10.3324/haematol.2020.272500.
9
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.评估阿卡替尼在治疗慢性淋巴细胞白血病中的药代动力学。
Expert Opin Drug Metab Toxicol. 2021 Sep;17(9):1023-1030. doi: 10.1080/17425255.2021.1955855. Epub 2021 Jul 28.
10
Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib.慢性淋巴细胞白血病的靶向治疗：阿卡拉布替尼的临床应用价值
Onco Targets Ther. 2021 Dec 29;14:5507-5519. doi: 10.2147/OTT.S303060. eCollection 2021.

引用本文的文献

1
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL.慢性淋巴细胞白血病（CLL）治疗期间的新冠病毒疾病（COVID-19）疫苗接种与COVID-19死亡的关系
Blood Adv. 2024 Oct 22;8(20):5262-5265. doi: 10.1182/bloodadvances.2024014121.
2
Outcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis.慢性淋巴细胞白血病患者感染新型冠状病毒肺炎的结局：一项系统评价和荟萃分析
Rev Assoc Med Bras (1992). 2024 Aug 16;70(8):e20240322. doi: 10.1590/1806-9282.20240322. eCollection 2024.
3
Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024).

本文引用的文献

1
The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID-19 and Hypertension: A Mini-Review.不同类别抗高血压药物对新冠肺炎合并高血压患者的影响：一篇综述
Int J Hypertens. 2022 Jan 21;2022:5937802. doi: 10.1155/2022/5937802. eCollection 2022.
2
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia.接种疫苗的 B 细胞慢性淋巴细胞白血病患者对 SARS-CoV-2 德尔塔变异株的中和能力受损。
J Hematol Oncol. 2022 Jan 9;15(1):3. doi: 10.1186/s13045-021-01219-7.
3
Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia.
布鲁顿酪氨酸激酶抑制剂安全性临床管理的循证专家共识（2024年）
Chin J Cancer Res. 2024 Jun 30;36(3):240-256. doi: 10.21147/j.issn.1000-9604.2024.03.02.
慢性淋巴细胞白血病患者接种BNT162b2 mRNA疫苗后的血清学反应。
Leuk Lymphoma. 2022 Feb;63(2):503-505. doi: 10.1080/10428194.2021.1973673. Epub 2021 Nov 2.
4
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.COVID-19 严重程度和死亡率在 CLL 患者中的研究：国际 ERIC 和 Campus CLL 研究的更新。
Leukemia. 2021 Dec;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Epub 2021 Nov 1.
5
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.慢性淋巴细胞白血病患者的COVID-19：生存结果改善及管理策略更新
Blood. 2021 Nov 4;138(18):1768-1773. doi: 10.1182/blood.2021011841.
6
Factors associated with clinical severity in emergency department patients presenting with symptomatic SARS-CoV-2 infection.出现有症状的SARS-CoV-2感染的急诊科患者临床严重程度的相关因素。
J Am Coll Emerg Physicians Open. 2021 Jun 29;2(4):e12453. doi: 10.1002/emp2.12453. eCollection 2021 Aug.
7
Risk Factors for COVID-19 in Patients with Hypertension.高血压患者感染新型冠状病毒肺炎的风险因素
Can J Infect Dis Med Microbiol. 2021 May 7;2021:5515941. doi: 10.1155/2021/5515941. eCollection 2021.
8
Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study.慢性呼吸系统疾病是 COVID-19 住院患者发生严重结局的预测因素：一项全国性研究。
Eur Respir J. 2021 Dec 9;58(6). doi: 10.1183/13993003.04474-2020. Print 2021 Dec.
9
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study.在英格兰 690 万人中，体重指数与 COVID-19 严重程度的关联：一项前瞻性、基于社区的队列研究。
Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-359. doi: 10.1016/S2213-8587(21)00089-9. Epub 2021 Apr 28.
10
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy.接受B细胞耗竭免疫疗法治疗的非霍奇金淋巴瘤患者感染新冠病毒后住院时间延长且死亡率更高。
Am J Hematol. 2021 Aug 1;96(8):934-944. doi: 10.1002/ajh.26209. Epub 2021 May 12.